Core IP Royalty Rates. Artiva shall pay to GCLC a royalty equal to [***] on Net Sales of each Licensed Product, including each Exercised Selected Product, the manufacture, use or sale of which is claimed by or uses any GCLC Core Technology, on a country-by-country and Licensed Product-by-Licensed Product basis during the Core IP Royalty Term, subject to the applicable adjustments in accordance with Section 6.1(e) below (the “Core IP Royalties”).
Appears in 4 contracts
Samples: Option and License Agreement (Artiva Biotherapeutics, Inc.), Option and License Agreement (Artiva Biotherapeutics, Inc.), Option and License Agreement (Artiva Biotherapeutics, Inc.)
